Humanized Chimeric Antigen Receptor T Cells Against CD19 With Cytokine Release Syndrome (CRS) Suppression Technology for Refractory/Relapsed CD19+ Acute Lymphoblastic Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 28 May 2018
At a glance
- Drugs Chimeric-antigen-receptor-T-cell-therapeutics-Shanghai-Unicar-Therapy-Bio-medicine-Technology (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Shanghai Unicar-Therapy Bio-medicine Technology
- 21 May 2018 Status changed from not yet recruiting to recruiting.
- 08 Oct 2017 Planned initiation date changed from 18 Sep 2017 to 18 Oct 2017.
- 11 Sep 2017 New trial record